MedKoo Biosciences, Inc.
Tel:   +1-919-636-5577    Fax:   +1-919-980-4831    Email:   sales@medkoo.com
Search
Login Register
Search
MedKoo Cat#: 561700 | Name: Rizatriptan

Description:

WARNING: This product is for research use only, not for human or veterinary use.

Rizatriptan is a serotonin-1b and serotonin-1d receptor agonist.

Chemical Structure

Rizatriptan
Rizatriptan
CAS#144034-80-0

Theoretical Analysis

MedKoo Cat#: 561700

Name: Rizatriptan

CAS#: 144034-80-0

Chemical Formula: C15H19N5

Exact Mass: 269.1640

Molecular Weight: 269.35

Elemental Analysis: C, 66.89; H, 7.11; N, 26.00

Price and Availability

This product is currently not in stock but may be available through custom synthesis. To ensure cost efficiency, the minimum order quantity is 1 gram. The estimated lead time is 2 to 4 months, with pricing dependent on the complexity of the synthesis (typically high for intricate chemistries). Quotes for quantities below 1 gram will not be provided. To request a quote, please click the button below. Note: If this product becomes available in stock in the future, pricing will be listed accordingly.
Bulk Inquiry
Related CAS #
No Data
Synonym
Rizatriptan; Risatriptan; MK 462 free base;
IUPAC/Chemical Name
2-(5-((1H-1,2,4-Triazol-1-yl)methyl)-1H-indol-3-yl)-N,N-dimethylethanamine
InChi Key
ULFRLSNUDGIQQP-UHFFFAOYSA-N
InChi Code
InChI=1S/C15H19N5/c1-19(2)6-5-13-8-17-15-4-3-12(7-14(13)15)9-20-11-16-10-18-20/h3-4,7-8,10-11,17H,5-6,9H2,1-2H3
SMILES Code
CN(C)CCC1=CNC2=C1C=C(CN3N=CN=C3)C=C2
Appearance
Solid powder
Purity
>98% (or refer to the Certificate of Analysis)
Shipping Condition
Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.
Storage Condition
Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).
Solubility
Soluble in DMSO
Shelf Life
>2 years if stored properly
Drug Formulation
This drug may be formulated in DMSO
Stock Solution Storage
0 - 4 C for short term (days to weeks), or -20 C for long term (months).
HS Tariff Code
2934.99.9001
More Info

Preparing Stock Solutions

The following data is based on the product molecular weight 269.35 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
1: Tradtrantip L, Jin BJ, Yao X, Anderson MO, Verkman AS. Aquaporin-Targeted Therapeutics: State-of-the-Field. Adv Exp Med Biol. 2017;969:239-250. doi: 10.1007/978-94-024-1057-0_16. Review. PubMed PMID: 28258578; PubMed Central PMCID: PMC5628614. 2: Maasumi K, Tepper SJ, Kriegler JS. Menstrual Migraine and Treatment Options: Review. Headache. 2017 Feb;57(2):194-208. doi: 10.1111/head.12978. Epub 2016 Dec 2. Review. PubMed PMID: 27910087. 3: Allais G, Benedetto C. Spotlight on frovatriptan: a review of its efficacy in the treatment of migraine. Drug Des Devel Ther. 2016 Oct 3;10:3225-3236. eCollection 2016. Review. PubMed PMID: 27757013; PubMed Central PMCID: PMC5055118. 4: Capi M, Curto M, Lionetto L, de Andrés F, Gentile G, Negro A, Martelletti P. Eletriptan in the management of acute migraine: an update on the evidence for efficacy, safety, and consistent response. Ther Adv Neurol Disord. 2016 Sep;9(5):414-23. doi: 10.1177/1756285616650619. Epub 2016 Jun 3. Review. PubMed PMID: 27582896; PubMed Central PMCID: PMC4994780. 5: Kacperski J, Hershey AD. Newly Approved Agents for the Treatment and Prevention of Pediatric Migraine. CNS Drugs. 2016 Sep;30(9):837-44. doi: 10.1007/s40263-016-0375-y. Review. PubMed PMID: 27503180. 6: Kassem AA. Formulation Approaches of Triptans for Management of Migraine. Curr Drug Deliv. 2016;13(6):882-98. Review. PubMed PMID: 27109335. 7: Richer L, Billinghurst L, Linsdell MA, Russell K, Vandermeer B, Crumley ET, Durec T, Klassen TP, Hartling L. Drugs for the acute treatment of migraine in children and adolescents. Cochrane Database Syst Rev. 2016 Apr 19;4:CD005220. doi: 10.1002/14651858.CD005220.pub2. Review. PubMed PMID: 27091010. 8: Patniyot IR, Gelfand AA. Acute Treatment Therapies for Pediatric Migraine: A Qualitative Systematic Review. Headache. 2016 Jan;56(1):49-70. doi: 10.1111/head.12746. Review. PubMed PMID: 26790849. 9: Becker WJ. Acute Migraine Treatment. Continuum (Minneap Minn). 2015 Aug;21(4 Headache):953-72. doi: 10.1212/CON.0000000000000192. Review. PubMed PMID: 26252584. 10: Cameron C, Kelly S, Hsieh SC, Murphy M, Chen L, Kotb A, Peterson J, Coyle D, Skidmore B, Gomes T, Clifford T, Wells G. Triptans in the Acute Treatment of Migraine: A Systematic Review and Network Meta-Analysis. Headache. 2015 Jul-Aug;55 Suppl 4:221-35. doi: 10.1111/head.12601. Epub 2015 Jul 14. Review. PubMed PMID: 26178694. 11: Becker WJ. Acute Migraine Treatment in Adults. Headache. 2015 Jun;55(6):778-93. doi: 10.1111/head.12550. Epub 2015 Apr 15. Review. PubMed PMID: 25877672. 12: Sakai F. Oral triptans in children and adolescents: an update. Curr Pain Headache Rep. 2015 Mar;19(3):8. doi: 10.1007/s11916-015-0478-z. Review. PubMed PMID: 25754598. 13: Bhambri R, Mardekian J, Liu LZ, Schweizer E, Ramos E. A review of the pharmacoeconomics of eletriptan for the acute treatment of migraine. Int J Gen Med. 2015 Jan 12;8:27-36. doi: 10.2147/IJGM.S73673. eCollection 2015. Review. PubMed PMID: 25624770; PubMed Central PMCID: PMC4296958. 14: Marmura MJ, Silberstein SD, Schwedt TJ. The acute treatment of migraine in adults: the american headache society evidence assessment of migraine pharmacotherapies. Headache. 2015 Jan;55(1):3-20. doi: 10.1111/head.12499. Review. PubMed PMID: 25600718. 15: Obermann M, Strupp M. Current treatment options in vestibular migraine. Front Neurol. 2014 Dec 4;5:257. doi: 10.3389/fneur.2014.00257. eCollection 2014. Review. PubMed PMID: 25538676; PubMed Central PMCID: PMC4255594. 16: Saracco MG, Allais G, Tullo V, Zava D, Pezzola D, Reggiardo G, Omboni S, Benedetto C, Bussone G, Aguggia M. Efficacy of frovatriptan and other triptans in the treatment of acute migraine of normal weight and obese subjects: a review of randomized studies. Neurol Sci. 2014 May;35 Suppl 1:115-9. doi: 10.1007/s10072-014-1752-2. Review. PubMed PMID: 24867847. 17: Franconi F, Finocchi C, Allais G, Omboni S, Tullo V, Campesi I, Reggiardo G, Benedetto C, Bussone G. Gender and triptan efficacy: a pooled analysis of three double-blind, randomized, crossover, multicenter, Italian studies comparing frovatriptan vs. other triptans. Neurol Sci. 2014 May;35 Suppl 1:99-105. doi: 10.1007/s10072-014-1750-4. Review. PubMed PMID: 24867845; PubMed Central PMCID: PMC4035544. 18: Belvis R, Mas N, Aceituno A. Migraine attack treatment : a tailor-made suit, not one size fits all. Recent Pat CNS Drug Discov. 2014 Apr;9(1):26-40. Review. PubMed PMID: 24605940. 19: Cui XP, Ye JX, Lin H, Mu JS, Lin M. Efficacy, safety, and tolerability of telcagepant in the treatment of acute migraine: a meta-analysis. Pain Pract. 2015 Feb;15(2):124-31. doi: 10.1111/papr.12158. Epub 2013 Dec 30. Review. PubMed PMID: 24382126. 20: Ramón-Carbajo C, Alvarez-Escudero R, Pascual J. [Rizatriptan: experience after 15 years of clinical use]. Rev Neurol. 2013 Dec 16;57(12):549-55. Review. Spanish. PubMed PMID: 24288104.

View History

Golidocitinib free base

Golidocitinib free base

Featured